drugset / Trial / NCT04171115
Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects
Phase 1
Completed
40 enrolled
Alachua Government Services, Inc.
United States Department of Defense · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose cohorts of 10 subjects (1: 10mg, 2: 25mg, 3: 50mg, 4: 100mg).
Timeline
- Start
- 2020-06-01
- Primary completion
- 2022-08-20
- Completion
- 2023-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G03-52-01 | Unknown | 10 mg | Intramuscular |
| Subject | G03-52-01 | Unknown | 25 mg | Intramuscular |
| Subject | G03-52-01 | Unknown | 50 mg | Intramuscular |
| Subject | G03-52-01 | Unknown | 100 mg | Intramuscular |
Indications
No indication recorded.